Ameriprise Financial Boosts Stake in Exact Sciences

Investment firm increases holdings in medical research company by over 100%

Mar. 17, 2026 at 7:08am

Got story updates? Submit your updates here. ›

Ameriprise Financial Inc. has significantly increased its position in Exact Sciences Corporation (NASDAQ:EXAS), a medical research company, by adding over 2.3 million shares during the third quarter. The investment firm now owns approximately 4.5 million shares, or 2.37% of Exact Sciences' stock.

Why it matters

This move by a major institutional investor signals increased confidence in Exact Sciences' long-term prospects. As a leader in molecular diagnostics and cancer screening, Exact Sciences' growth could benefit from Ameriprise's larger stake and potential influence.

The details

According to a recent SEC filing, Ameriprise Financial increased its holdings in Exact Sciences by 105.8% during the third quarter of 2026. The firm now owns 4,493,085 shares of the medical research company's stock, up from 2,182,946 shares held previously.

  • Ameriprise Financial increased its Exact Sciences holdings in the 3rd quarter of 2026.

The players

Ameriprise Financial Inc.

A diversified financial services firm that provides wealth management, asset management, insurance, annuities and other financial products and services.

Exact Sciences Corporation

A molecular diagnostics company focused on the early detection and prevention of cancer, best known for its Cologuard colorectal cancer screening test.

Got photos? Submit your photos here. ›

The takeaway

Ameriprise's substantial increase in its Exact Sciences holdings suggests the investment firm sees significant long-term growth potential in the medical research company's cancer screening and diagnostics business.